Cartesian Therapeutics Inc (RNAC)
EBITDA Growth
5.61%
Quarterly · Period ending:
RNAC EBITDA Growth
Year-over-year change vs the same period a year earlier
Latest reported5.61%period ending
Latest reported5.61%period ending
RNAC Quarterly EBITDA YoY % (-30.35% → 5.61%)
Year-over-year change
High-resolution chart · PNG
RNAC ebitda growth history
Quarterly. Dates are reporting period ends; fiscal years can differ from calendar years.
| Period ending | EBITDA Growth |
|---|---|
| 5.6146% | |
| -132.9769% | |
| -967.0992% | |
| -47.7005% | |
| 17.4102% | |
| 70.7738% | |
| 95.1728% | |
| -216.9363% | |
| 234.162% | |
| -174.3038% | |
| -3,051.8413% | |
| -6.7686% | |
| -208.26% | |
| -169.2083% | |
| -50.6783% | |
| -595.0787% | |
| 73.1052% | |
| 226.0019% | |
| 193.0982% | |
| 88.9924% | |
| 123.498% | |
| -23.8701% | |
| -11.0438% | |
| 19.0777% | |
| -50.3799% | |
| -66.2695% | |
| 7.2637% | |
| 26.0167% | |
| 12.4064% | |
| 25.1936% | |
| 25.9552% | |
| -8.5093% | |
| -16.4192% | |
| -4.8434% | |
| -40.7139% | |
| -96.3516% | |
| -140.9834% | |
| -109.7739% | |
| -105.6655% | |
| -39.9613% | |
| -5.6204% | |
| -30.3488% |